The increased expression of the CTLA-4 molecule found in the T cell compartment in CLL patients seems to be an unfavourable factor, because it specifically inhibits anti-tumour immunity in these patients [15–17]. Here, CTLA4 is linked to B-cell chronic lymphocytic leukemia.